Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Higham (Manchester, United Kingdom), P. Karur (Manchester, United Kingdom), N. Jackson (Manchester, United Kingdom), D. Cunoosamy (Gothenburg, Sweden), P. Jansson (Gothenburg, Sweden), D. Singh (Manchester, United Kingdom). Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells. 5254

Member's Comments

No comment yet.

Related content which might interest you: Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma Source: Eur Respir J 2010; 35: 750-756 Year: 2010 p38 MAPK inhibitors in COPD Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung Year: 2012 The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Inhibition of P38 kinase does not reduce production of TNF-alpha from airway cells in COPD Source: Annual Congress 2007 - Epithelial networks in the airways Year: 2007 Effect of non-steroidal anti-inflammatory drugs on neutrophil recruitment, p38 map kinase phosphorylation and NF-κB activation in lung from mice exposed to cigarette smoke Source: Annual Congress 2007 - Molecular pathogenesis: focus on COPD and asthma Year: 2007 Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013 Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Corticosteroids reduce pro-inflammatory cytokine expression in airway smooth muscle cells via upregulation of MAPK phosphatase-1 and inhibition of p38 MAPK signalling Source: Eur Respir J 2005; 26: Suppl. 49, 713s Year: 2005 The p38 MAP kinase inhibitor dilmapimod ameliorates airway inflammation induced by ozone challenge in healthy volunteers Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012 Expression of phosphorylated p38 MAPK in the lung of smokers with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 582s Year: 2006 The pan janus kinase (JAK) inhibitor KN-002 suppresses inflammatory mediator release from severe asthma bronchial epithelial cells. Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017 Increased activation of p38 MAPK in COPD Source: Eur Respir J 2008; 31: 62-69 Year: 2008 Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017 AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 Ceramide-1-phosphate decreases allergic airway inflammation, remodeling and hyperresponsiveness by inhibition of phosphorilation of NF-kappa B, Akt, MAPK p-38 in dendritic cells Source: Annual Congress 2010 - Models of airways disease Year: 2010 PF-03715455: An inhaled p38 inhibitor for the treatment of chronic obstructive pulmonary disease Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Increased expression of p38 MAPK in human bronchial epithelium after lipopolysaccharide exposure Source: Eur Respir J 2005; 25: 797-803 Year: 2005 Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009